Dr. Nicole Saphier breaks down two major health policy stories making headlines right now.

First, Robert F. Kennedy Jr. signals a potential shift in how the FDA approaches peptides—a fast-growing but loosely regulated space in wellness, anti-aging, and performance medicine. What could tighter FDA oversight mean for patients, doctors, and access to these treatments? Dr. Saphier explains why more regulation could actually lead to safer use, better data, and even future insurance coverage.

Then, attention turns to leadership at the Centers for Disease Control and Prevention. With no confirmed director and rising public health concerns—including a troubling measles resurgence—reports suggest the White House may be eyeing a new candidate to restore credibility and unify messaging. Why this role matters now more than ever—and what strong leadership could mean for public trust.

🔍 In this episode:

• FDA peptide regulation: risks, benefits, and what comes next
• The science vs. hype behind peptides in wellness and medicine
• CDC leadership vacuum and why it matters for public health
• Measles outbreaks, vaccine skepticism, and restoring trust

Stay informed with your weekly rundown of the biggest stories in health, medicine, and policy.